This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients
by Zacks Equity Research
Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
by Kanishka Das
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
by Kinjel Shah
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Pfizer (PFE) closed at $25.62 in the latest trading session, marking a +1.51% move from the prior day.
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
by Kinjel Shah
AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
by Zacks Equity Research
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
by Zacks Equity Research
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
by Kinjel Shah
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
by Kinjel Shah
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
by Zacks Equity Research
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
by Zacks Equity Research
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
by Ekta Bagri
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
In the closing of the recent trading day, Pfizer (PFE) stood at $24.31, denoting a +1.17% move from the preceding trading day.
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
by Kinjel Shah
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
by Sundeep Ganoria
ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost top-line growth.
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
by Ekta Bagri
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
by Kinjel Shah
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Slowing Gardasil Sales Hurt MRK's Top Line: Is Recovery in the Cards?
by Zacks Equity Research
Merck's Gardasil sales decline due to weak demand trends in China, with new launches expected to offset the downside.
Should Value Investors Buy Pfizer (PFE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.